Wells Fargo
APRE icon

Wells Fargo’s Aprea Therapeutics APRE Stock Holding History

Wells Fargo’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250
Closed -$1.02K – 6904
2024
Q2 		$1.02K Sell
250
-22
-8% -$113 ﹤0.01% 6091
2024
Q1 		$1.82K Hold
272
– – ﹤0.01% 6051
2023
Q4 		$1.28K Buy
272
+2
+0.7% +$8 ﹤0.01% 6175
2023
Q3 		$1.13K Sell
270
-3
-1% -$11 ﹤0.01% 6178
2023
Q2 		$860 Buy
273
+9
+3% +$34 ﹤0.01% 6352
2023
Q1 		$1.17K Hold
264
– – ﹤0.01% 6334
2022
Q4 		$1.75K Buy
264
+257
+3,671% +$2.71K ﹤0.01% 6042
2022
Q3 		$0 Sell
7
-23
-77% -$408 ﹤0.01% 6623
2022
Q2 		$0 Buy
30
+25
+500% +$576 ﹤0.01% 6761
2022
Q1 		$0 Hold
5
– – ﹤0.01% 7009
2021
Q4 		$0 Buy
+5
New +$442 ﹤0.01% 7185
2021
Q2 		– Sell
-1,515
Closed -$155K – 6876
2021
Q1 		$155K Buy
1,515
+1,239
+449% +$145K ﹤0.01% 5280
2020
Q4 		$27K Sell
276
-343
-55% -$163K ﹤0.01% 5775
2020
Q3 		$298K Buy
619
+38
+7% +$21.3K ﹤0.01% 4719
2020
Q2 		$451K Buy
581
+232
+66% +$152K ﹤0.01% 4403
2020
Q1 		$242K Buy
349
+323
+1,242% +$237K ﹤0.01% 4560
2019
Q4 		$24K Buy
+26
New +$14.3K ﹤0.01% 5700

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's APRE Position: Q3 2024 in Review

Wells Fargo sold out of Aprea Therapeutics (APRE) in Q3 2024, closing a stake of 250 shares — an estimated $1.02K sold.

Wells Fargo first reported a position in APRE in Q4 2019 and held it in 17 quarters. The position peaked at $451K in Q2 2020. 22 funds tracked by Wall St. Rank hold APRE as of Q3 2024.

  • Wells Fargo reported no remaining Aprea Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wells Fargo sold 250 Aprea Therapeutics shares in Q3 2024, an estimated $1.02K.
  • Wells Fargo first reported a position in Aprea Therapeutics in Q4 2019 and held it in 17 quarters.
  • Wells Fargo's Aprea Therapeutics position peaked at $451K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.